GlassScriptPhysician profile
David R Jones
NPI 1790807022
$6,501.50
in general payments reported to CMS, 2019-2025
26 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $1,396 · 2023: $1,798 · 2024: $1,337 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,868.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,066.36 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $892.64 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $760.96 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $588.14 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $495.05 | 2022-2025 | Lybalvi, Aristada |
| Bausch Health US, LLC | $425.16 | 2022-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $410.86 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $381.81 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $207.59 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $202.52 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $168.08 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $151.06 | 2021-2025 | Adzenys Xr-Odt, Exxua |
| Jazz Pharmaceuticals INC. | $139.34 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $127.47 | 2022-2024 | Jornay Pm |
| Corium, LLC | $117.57 | 2022-2024 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $90.83 | 2022-2025 | Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $64.50 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $51.81 | 2024-2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $49.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $18.38 | 2023 | Belsomra |
| Indivior INC. | $17.54 | 2023 | Perseris |
| Eisai INC. | $16.54 | 2022 | |
| Novo Nordisk INC | $15.38 | 2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $14.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.01 | 2025 | Cobenfy |
| Almatica Pharma LLC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.